시장보고서
상품코드
1429719

세계의 알파 만노시도시스 시장 보고서(2024년)

Alpha Mannosidosis Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 200 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

알파 만노시도시스 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 연평균 18.0%의 복합 성장률(CAGR)로 296억 2,000만 달러에 달할 것으로 예상됩니다. 이러한 성장은 세계 인구 증가, 도시화, E-Commerce 확대, 스포츠웨어 수요 증가, 소셜 미디어의 확산으로 인한 신흥 경제국에서 조직화된 소매업의 부상에 의해 촉진될 것으로 예상됩니다. 주요 동향으로는 효소 요법의 사용 증가, 조혈모세포 이식의 채택, 대혈관 주입의 적용 등이 있습니다.

알파 만노시도시스 시장의 성장은 희귀질환 치료제 승인에 대한 규제 지원이 증가함에 따라 촉진될 것으로 예상됩니다. 환자 수가 적은 질환에 대한 임상시험을 수행하는 데 있어 고유한 도전과제는 규제적 노력을 통해 해결되고 있습니다. 주목할 만한 점은 2021년 미국 식품의약국(FDA)이 제한된 환자 집단으로 인한 어려움을 인식하고 희귀질환에 대한 새로운 치료법 개발 및 평가에 대한 지원을 우선순위로 삼았다는 점입니다. 희귀질환 치료제에 희귀의약품 지정을 부여하는 FDA의 권한은 조건부 임상시험에 대한 세금 공제, 사용자 수수료 면제, 승인 후 7년간의 시장 독점권 등의 인센티브를 스폰서에게 제공합니다. 이 규정의 지원으로 알파-만노시도증 시장은 앞으로 나아갈 준비가 되어 있습니다.

알파 만노시도시스 시장의 성장은 의료비 증가에 크게 영향을 받습니다. 의료 지출에는 가족 계획 서비스, 영양 프로그램, 응급 의료 지원 및 보건 서비스 관련 비용이 포함됩니다. 정부 이니셔티브, 보조금 및 인센티브는 알파 만노시도시스을 포함한 희귀 질환 분야에서 재정적 지원을 제공하고 연구 개발을 장려하는 데 중요한 역할을 합니다. 예를 들어, 2023년 6월 미국 메디케어-메디케이드 서비스 센터(CMS)가 발표한 데이터에 따르면 2021년 미국의 국민의료비(NHE)는 4조 3,000억 달러에 달해 국내총생산(GDP)의 18.3%를 차지했습니다. 이러한 의료비 증가는 희귀질환에 대한 치료법 개발 및 희귀질환 치료법 발전에 기여하기 위한 노력을 반영하고 있습니다. 그 결과, 의료비 지출 증가는 알파만노사이드증 시장을 견인할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 알파 만노시도시스 시장, 치료별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 골수 이식(BMT)
  • 효소보충요법(ERT)
  • 기타 치료
  • 세계의 알파 만노시도시스 시장, 적응증별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 유형 I
  • 유형 II
  • 유형 III
  • 세계의 알파 만노시도시스 시장, 최종사용자별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원
  • 전문 클리닉

제7장 지역 및 국가 분석

  • 세계의 알파 만노시도시스 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 알파 만노시도시스 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • 알파 만노시도시스 시장 경쟁 상황
  • 알파 만노시도시스 시장 기업 개요
    • Chiesi Farmaceutici SpA
    • Cipla
    • EdiGene Inc.
    • Immunochina
    • Takara Bio

제31장 기타 주요 및 혁신적인 기업

  • Daiichi Sankyo Company
  • Ultragenyx Pharmaceutical Inc
  • Mitsubishi Tanabe Pharma
  • Oxford Biomedica plc
  • Santen Pharmaceutical Co.
  • Merck
  • GenScript
  • Cellular Biomedicine Group
  • GE Healthcare
  • Lonza
  • Nikon CeLL innovation Co. Ltd.
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Novartis AG
  • Amgen

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.26

Alpha mannosidosis is a rare genetic disorder characterized by the body's inability to effectively break down specific groups of complex sugars, leading to the accumulation of these sugars in various organs and systems, including the central nervous system. The impact of sugar buildup can vary significantly from person to person.

The primary therapeutic approaches for alpha mannosidosis include bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow transplant involves replacing dysfunctional marrow with healthy marrow to address the underlying genetic defect. Enzyme replacement therapy aims to supplement or replace a deficient enzyme in individuals lacking the enzyme or having a deficiency. The indications for alpha mannosidosis are classified into Type I, Type II, and Type III, and these therapeutic interventions are implemented across various healthcare settings, including hospitals and specialty clinics. These treatments play a crucial role in managing the symptoms and addressing the underlying genetic abnormalities associated with alpha mannosidosis.

The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with an alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $12.77 billion in 2023 to $15.26 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The growth observed in the historical period can be attributed to several factors, including the expansion of emerging markets, urbanization trends, heightened demand for man-made fibers, and government initiatives supporting the textile industry.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $29.62 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%. The forecasted growth is fueled by global population growth, urbanization, e-commerce expansion, increased sportswear demand, and the rise of organized retail in developing economies, driven by social media penetration. Key trends include the growing use of enzyme therapy, adoption of hematopoietic stem cell transplantation, and the application of cisterna magna infusion.

The anticipated growth in the alpha mannosidosis market is expected to be driven by rising regulatory support for drug approval targeting rare diseases. The inherent challenge of conducting clinical trials for diseases with a small patient population is being addressed through regulatory initiatives. Notably, in 2021, the U.S. Food and Drug Administration (FDA) prioritized support for the development and evaluation of new treatments for rare diseases, recognizing the difficulties posed by limited patient populations. The FDA's authority to grant orphan drug designation for drugs addressing rare diseases provides sponsors with incentives such as tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. This regulatory backing is poised to propel the alpha mannosidosis market forward.

The growth of the alpha mannosidosis market is significantly influenced by the increasing healthcare expenditure. Healthcare expenditure encompasses costs related to family planning services, nutrition programs, emergency medical assistance, and health services. Government initiatives, grants, and incentives play a crucial role in providing financial support and encouraging research and development in the field of rare diseases, including alpha mannosidosis. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 indicates that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). This growing healthcare expenditure reflects a commitment to supporting healthcare initiatives, contributing to the advancement of treatments for rare diseases. Consequently, the increasing healthcare expenditure is expected to drive the alpha mannosidosis market.

Major companies in the alpha mannosidosis market are actively focused on developing enzyme replacement therapies to address rare alpha-mannosidosis. Enzyme replacement therapy involves supplying exogenous alpha-mannosidase, which helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs, a characteristic feature of alpha-mannosidosis contributing to its pathological effects. A notable example is Chiesi Global Rare Diseases, a U.S.-based pharmaceutical company, which, in February 2023, launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis. Lamzede acts similarly to the human body's alpha-mannosidase enzyme, restoring normal cellular activity in patients. The treatment involves a weekly injection of 10 mg of Lamzede.

The alpha mannosidosis market is further propelled by a significant surge in biopharmaceutical research and development (R&D) investments. The emphasis on R&D reflects the commitment of pharmaceutical companies and academic institutions to advancing innovative treatments for alpha mannosidosis. Advancements in genetic therapies and a deeper understanding of the molecular basis of alpha mannosidosis have contributed to the development of potential treatments. Examples of increased R&D investments include the UK government's announcement of a spending of $18.9 billion (£15.3 billion) in pharmaceutical R&D in 2020, with an allocated budget of $49.2 billion (£39.8 billion) for 2022-2025. Moreover, in March 2023, Merck, a Germany-based biopharmaceuticals manufacturer, reported a 3.9% increase in R&D spending for the year 2022 compared to 2021. Similarly, Roche Holding AG, a Switzerland-based biopharmaceuticals manufacturer, announced a 3.7% increase in R&D expenditure for the year 2022 compared to 2021. These increased investments in research and development by biopharmaceutical companies underscore the momentum driving the alpha mannosidosis market forward.

In April 2023, Italian pharmaceutical company Chiesi Farmaceutici acquired Amryt Pharma, a UK-based pharmaceutical company, for $1.25 billion. This strategic acquisition enhances Chiesi's Global Rare Diseases business division by incorporating Amryt Pharma's approved commercial products for rare diseases into its existing portfolio. Amryt Pharma is recognized for its dedication to developing and delivering innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market report are Chiesi Farmaceutici S.p.A., Cipla, EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc., Mitsubishi Tanabe Pharma, Oxford Biomedica PLC, Santen Pharmaceutical Co., Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, Lonza, Nikon CeLL innovation Co. Ltd., Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd., Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma PLC, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Bayer AG, Lyric Opera of Chicago, AMC Entertainment Holdings Inc., Regal Entertainment Group, Carmike Cinemas Inc., Ultragenyx, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca PLC, Biotchpharma, Gene Vector Technologies, BrainStorm Cell Therapeutics, Pluristem, Biogen SA, Sanofi, Adcock Ingram

North America was the largest region in the alpha mannosidosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha Mannosidosis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha mannosidosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha mannosidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Therapy Type: Bone Marrow Transplant (BMT); Enzyme Replacement Therapy (ERT); Other Therapies
  • 2) By Indication: Type I; Type II; Type III
  • 3) By End-User: Hospitals; Specialty Clinics
  • Companies Mentioned: Chiesi Farmaceutici S.p.A.; Cipla; EdiGene Inc.; Immunochina; Takara Bio
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha Mannosidosis Market Characteristics

3. Alpha Mannosidosis Market Trends And Strategies

4. Alpha Mannosidosis Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Alpha Mannosidosis Market Size and Growth

  • 5.1. Global Alpha Mannosidosis Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Alpha Mannosidosis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Alpha Mannosidosis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Alpha Mannosidosis Market Segmentation

  • 6.1. Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bone Marrow Transplant (BMT)
  • Enzyme Replacement Therapy (ERT)
  • Other Therapies
  • 6.2. Global Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type I
  • Type II
  • Type III
  • 6.3. Global Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics

7. Alpha Mannosidosis Market Regional And Country Analysis

  • 7.1. Global Alpha Mannosidosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Alpha Mannosidosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Alpha Mannosidosis Market

  • 8.1. Asia-Pacific Alpha Mannosidosis Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Alpha Mannosidosis Market

  • 9.1. China Alpha Mannosidosis Market Overview
  • 9.2. China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Alpha Mannosidosis Market

  • 10.1. India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Alpha Mannosidosis Market

  • 11.1. Japan Alpha Mannosidosis Market Overview
  • 11.2. Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Alpha Mannosidosis Market

  • 12.1. Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Alpha Mannosidosis Market

  • 13.1. Indonesia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Alpha Mannosidosis Market

  • 14.1. South Korea Alpha Mannosidosis Market Overview
  • 14.2. South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Alpha Mannosidosis Market

  • 15.1. Western Europe Alpha Mannosidosis Market Overview
  • 15.2. Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Alpha Mannosidosis Market

  • 16.1. UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Alpha Mannosidosis Market

  • 17.1. Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Alpha Mannosidosis Market

  • 18.1. France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Alpha Mannosidosis Market

  • 19.1. Italy Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Alpha Mannosidosis Market

  • 20.1. Spain Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Alpha Mannosidosis Market

  • 21.1. Eastern Europe Alpha Mannosidosis Market Overview
  • 21.2. Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Alpha Mannosidosis Market

  • 22.1. Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Alpha Mannosidosis Market

  • 23.1. North America Alpha Mannosidosis Market Overview
  • 23.2. North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Alpha Mannosidosis Market

  • 24.1. USA Alpha Mannosidosis Market Overview
  • 24.2. USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Alpha Mannosidosis Market

  • 25.1. Canada Alpha Mannosidosis Market Overview
  • 25.2. Canada Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Alpha Mannosidosis Market

  • 26.1. South America Alpha Mannosidosis Market Overview
  • 26.2. South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Alpha Mannosidosis Market

  • 27.1. Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Alpha Mannosidosis Market

  • 28.1. Middle East Alpha Mannosidosis Market Overview
  • 28.2. Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Alpha Mannosidosis Market

  • 29.1. Africa Alpha Mannosidosis Market Overview
  • 29.2. Africa Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Alpha Mannosidosis Market Competitive Landscape And Company Profiles

  • 30.1. Alpha Mannosidosis Market Competitive Landscape
  • 30.2. Alpha Mannosidosis Market Company Profiles
    • 30.2.1. Chiesi Farmaceutici S.p.A.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Cipla
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. EdiGene Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Immunochina
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Takara Bio
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Alpha Mannosidosis Market Other Major And Innovative Companies

  • 31.1. Daiichi Sankyo Company
  • 31.2. Ultragenyx Pharmaceutical Inc
  • 31.3. Mitsubishi Tanabe Pharma
  • 31.4. Oxford Biomedica plc
  • 31.5. Santen Pharmaceutical Co.
  • 31.6. Merck
  • 31.7. GenScript
  • 31.8. Cellular Biomedicine Group
  • 31.9. GE Healthcare
  • 31.10. Lonza
  • 31.11. Nikon CeLL innovation Co. Ltd.
  • 31.12. Gilead Sciences
  • 31.13. Bristol-Myers Squibb
  • 31.14. Novartis AG
  • 31.15. Amgen

32. Global Alpha Mannosidosis Market Competitive Benchmarking

33. Global Alpha Mannosidosis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha Mannosidosis Market

35. Alpha Mannosidosis Market Future Outlook and Potential Analysis

  • 35.1 Alpha Mannosidosis Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Alpha Mannosidosis Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Alpha Mannosidosis Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제